Geba to resign as director of FDA's Office of Generic Drugs

Greg Geba said in an internal memo that he will resign as director of FDA's Office of Generic Drugs (OGD), effective March 15. Geba, who became director last July, said two of the original reasons he joined the office -- to help "pave the way for extension of generics across the entire therapeutic spectrum" and "to address issues such as pill size, shape, color" and the potential effect on patients -- "would be challenged" by the realignment of OGD's CMC functions into the new Office of Pharmaceutical Quality. ...